Freyr support MAA Post Approval Submission s of Generic Medicinal products for EU member states to maintain the Regulatory compliance as per HAs by filing Variations and helps in streamlining the changes in formulation & Post-approval activities. After a marketing authorization application (MAA) is granted approval in European Union (EU), in view of commercialization of a product (minimize costs, time or other reasons), the manufacturer may consider making necessary changes. Such changes must be notified to the Health Authorities (HAs) by proposing a Post-approval change submission. As per the guidance, any changes proposed to the registered content in MAA shall be informed to HAs by filing Variations. Based on the impact of changes on quality of the medicinal product, they are categorised as: Major Changes: Have substantial potential to have an adverse effect on the identity, strength, quality, purity, or potency of a drug product / drug substance as these factors may relat...
Comments
Post a Comment